Cardiometabolic diseases refer to a group of medical conditions that involve the interplay of cardiovascular and metabolic factors. These conditions often include cardiovascular diseases (such as coronary artery disease and heart failure) and metabolic disorders (such as diabetes and obesity). Numerous companies are involved in the research, development, and production of products related to the diagnosis, management, and treatment of cardiometabolic diseases.
Amgen Received FDA approval for its Parsabiv (etelcalcetide) injection for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis.
AstraZeneca Initiated Phase 3 trial of Farxiga (dapagliflozin) for the prevention of cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease.
Boehringer Ingelheim Presented positive Phase 2 data for its GLP-1R agonist Efpeglenatide at the European Association for the Study of Diabetes (EASD) meeting, showing its potential for weight management and glycemic control in patients with type 2 diabetes.
Roche Entered into a multi-year collaboration with Verily (Alphabet subsidiary) to develop AI-powered tools for the personalized management of cardiometabolic diseases.
Novo Nordisk Partnered with Dexcom to integrate continuous glucose monitoring data with Novo Nordisk's insulin delivery systems, aiming to improve glycemic control and patient outcomes.
Abbott Collaborated with the American Diabetes Association (ADA) to launch a new initiative focused on improving diabetes education and self-management across diverse communities.
List of Cardiometabolic Disease Key Companies in the Market
Cardiometabolic Disease Market Size was valued at USD 125.3 billion in 2022 and is projected to grow from USD 155.37 Billion in 2023 to USD 868.45 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 24.00% during the forecast period (2023 - 2032). Rapidly changing lifestyles and the increasing prevalence of disorders like diabetes, hypertension, cardiovascular disease, and high cholesterol are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
One among the primary causes of death worldwide is due to cardiometabolic disorders (CMDs). An unhealthy lifestyle, physical inactivity, smoking, and improper food are the key contributors to these diseases. CMDs include chronic renal failure, diabetes mellitus, and cardiovascular illnesses (CVDs). For instance, the WHO reports that the main cause of mortality worldwide is cardiovascular diseases (CVDs), which claim an estimated 17.9 million lives annually. Coronary heart disease, rheumatic heart disease, cerebrovascular disease, and other illnesses are heart and blood vessel disorders known as CVDs. Heart attacks and strokes are responsible for more than four out of every five CVD deaths, and one-third of these deaths happen before age 70. Unhealthy eating habits, usage of tobacco products, and abusing alcohol are the main behavioral risk factors for heart disease and stroke. Individuals may experience elevated blood pressure, elevated blood glucose, elevated blood lipids, as well as overweight and obesity as a result of behavioral risk factors. The growing prevalence of CVDs is anticipated to boost the market CAGR during the coming years.
Health-related technology has developed quickly due to developments in computers, electronics, telecommunication, and medicine. For instance, the genetic preventative strategy can pinpoint those most at risk for the disease, enabling early intervention to improve their lifestyles. The NHS began using genomic analysis to determine the likelihood of developing heart disease in March 2021. The UK biotech company NHS, Genomics plc, and an Oxford University spin-off are collaborating on a pilot trial that will utilize genetic data to forecast the risk of heart disease. Genomics plc's integrated risk instrument (IRT) will calculate each patient's chance of having CVD during the next ten years. According to the business, applying the IRT to everyone in the UK between the ages of 40 and 60 would allow for identifying more than 650,000 people with high CVD risk who are currently ignored by screening. In addition, the traditional healthcare system has been greatly enhanced by current advancements in the Internet of Things (IoT), cloud computing, and artificial intelligence (AI). Thus, such factors are driving the Cardiometabolic Disease market revenue.
Based on Treatment, the market segments of cardiometabolic disease includes Angiotensin-converting Enzyme (ACE) Inhibitors, Diuretics, Glucophage, and Others. The Angiotensin-converting Enzyme (ACE) Inhibitors segment dominated the market due to the Treatment's utilization in the Treatment of hypertension and heart failure. In addition, the disease has a high prevalence due to the prevalence of comorbidities such as obesity and diabetes.
Figure 1: Cardiometabolic Disease Market, by Distribution Channel, 2022 & 2032 (USD billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Based on distribution channels, the Cardiometabolic Disease Market segmentation includes Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others. The Hospital Pharmacies category generated the most income. Growing number of hospitals and increasing need for drugs for treating CMDs to boost segmental growth.
By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Cardiometabolic Disease market area will dominate this market. Rising healthcare product demand and expanding economies are to blame for this region's rise. Another significant driver of the market expansion is the growing awareness of cardiometabolic disease among European consumers and the expansion of the healthcare sector.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: CARDIOMETABOLIC DISEASE MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's Cardiometabolic Disease market accounted for the second-largest market share in 2022. Rising R&D spending, high healthcare costs, and a well-established healthcare sector in this area. Further, the German market of Cardiometabolic Disease held the largest market share, and the UK market of Cardiometabolic Disease was the fastest growing market in the European region
The Asia-Pacific Cardiometabolic Disease Market is expected to grow at the fastest CAGR from 2023 to 2032. Due to the region's rapidly expanding medical infrastructures, stringent government regulations on public healthcare, and prominent manufacturers' adoption of various market expansion tactics, Asia Pacific had a sizeable market share during the anticipated period. Moreover, China’s market of Cardiometabolic Disease held the largest market share, and the Indian market of Cardiometabolic Disease was the fastest growing market in the Asia-Pacific region.
Cardiometabolic Disease Key Market Players & Competitive Insights
Leading market players are investing heavily in R&D to expand their product lines, which will help the market of Cardiometabolic Disease. Companies are also undertaking strategic activities to expand their global footprint, with important market developments including contractual agreements, mergers and acquisitions, new product launches, and collaboration with other companies.
In recent years, the Cardiometabolic Disease industry has offered some of the most significant products. Major players in the market of Cardiometabolic Disease include Cardax, Inc., Novartis AG, Novo Nordisk A/S, Eli Lilly and Company, Bayer AG, Allergan, Boehringer Ingelheim, International GmbH, AstraZeneca, and other players.
Cardax is a biopharmaceutical business in the development stage focused on creating medications for chronic conditions characterized by inflammation. An astaxanthin dietary supplement for inflammatory health, ZanthoSyn is marketed by Cardax, a consumer health firm. Until now, Cardax concentrated on creating medications for illnesses brought on by inflammation. CDX-101, the company's pre-clinical pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, and CDX-301, the pre-clinical pharmaceutical candidate for macular degeneration, may be made commercially available by Cardax.
The healthcare corporation Novartis AG specializes in developing, producing, and marketing prescription and over-the-counter drugs, as well as products for eye care. In addition, it offers medicines for treating solid tumors, immunological disorders, infections, cardiovascular illness, ophthalmic and respiratory diseases, dermatological issues, neurological disorders, cancer, and neurological disorders. Through Sandoz, the business provides biosimilars and generic medications. Through the Novartis Institutes for BioMedical Research (NIBR), Novartis researches several disease-related fields. The corporation has a network of subsidiaries and offices in the Americas, the Middle East, Europe, Africa, and Asia-Pacific. Basel, Switzerland, serves as the headquarters of Novartis.
Key Companies in the Cardiometabolic Disease market include
Cardiometabolic Disease Industry Developments
October 2022 To encourage medical professionals (HCPs) to prioritize an integrated strategy to care for cardio-renal-metabolic (C-R-M) conditions given the cardiovascular, renal (kidney), and metabolic systems' close interconnection and shared disease-related pathways, Eli Lilly and Company and Boehringer Ingelheim launched CRMSynced.
June 2021 The ACC and GE Healthcare worked together to create a roadmap for AI and digital cardiology technologies and novel approaches for better health outcomes with the help of and involvement in the ACC's Applied Health Innovation Consortium (AHIC).
August 2021 Bayer announced detailed data from the Phase III FIGARO-DKD research demonstrating that compared to placebo, the investigational medicine finerenone lowered the risk of cardiovascular (CV) disease in a broad population of patients with stages 1-4 of chronic kidney disease (CKD) and type 2 diabetes (T2D)
North America
Europe
Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)